Today: 20 May 2026
LSEG share price today: London Stock Exchange Group stock rises as buyback, regulation and index headlines land
10 February 2026
2 mins read

LSEG share price today: London Stock Exchange Group stock rises as buyback, regulation and index headlines land

London, Feb 10, 2026, 08:34 GMT — Regular session.

  • LSEG edged up roughly 0.5% in early trading to 7,560p, building on Monday’s 7,522p finish.
  • FTSE Russell pushed back its Indonesia index review. The FCA, for its part, laid out plans to release more comprehensive UK share-trading data.
  • LSEG announced another round of share buybacks as part of its ongoing repurchase program.

London Stock Exchange Group (LSEG.L) shares edged up 0.5% to 7,560 pence by 0835 GMT on Tuesday, picking up from Monday’s 7,522 close. So far, the stock’s been moving between 7,472 and 7,622 pence, set against a 52-week range stretching from 6,684 up to 11,915.

The London Stock Exchange’s parent — which also owns Refinitiv — finds itself once again caught up in market disputes over transparency and access. It’s not a trivial issue: a sizable portion of the company’s profits depends on investor trading volumes, demand for its data, and the disclosures regulators force firms to make.

Those headlines landed at an odd moment. Investors in London have been sizing up what qualifies as “real” liquidity and scrutinizing how index providers call a market investable. With passive funds shadowing those benchmarks, money shifts in a hurry whenever the rules change.

FTSE Russell has delayed its March review of Indonesia, saying another update will come before its global review set for May. The country classification announcement is still pegged for April 7. Effective immediately, the firm won’t add newly listed Indonesian stocks to its products, pointing to ongoing uncertainty over free float—shares available to trade. “The pause gives regulators time to fix free-float and data integrity issues properly,” said Mohit Mirpuri, fund manager at SGMC Capital. Reuters

Britain’s Financial Conduct Authority is looking to gather and release all trading data for shares listed in London, pulling in figures from every venue—including the dark pools favored by institutions. The move, pitched as a quick fix ahead of a full “consolidated tape” that would pull real-time equity data together in a single stream, comes as London tries to counter a slump in listings. “The truth is we have way more liquidity here than is often reported and that is just silly,” said Simon Walls, interim director of markets at the FCA. Reuters

LSEG highlighted fresh buyback activity, announcing it bought back 381,934 shares on Feb. 9 at an average 7,551.87 pence apiece. Those shares are set to be cancelled, which will bring total voting rights down to 505,721,098.

Traders in India reported that LSEG’s spot FX matching platform was back to normal after those Feb. 9 technical hiccups that slowed down trades on the dollar/rupee pair. The company hasn’t commented. “Bid-offer spreads were relatively wider in early trading,” said a trader at a Mumbai bank, pointing to the distance between buying and selling prices. Reuters

Risk appetite held up in early European hours, following gains across Asian equities where Tokyo’s Nikkei notched a new all-time high. Investors are eyeing a packed U.S. data slate later this week, which could sway views on interest rates.

Still, risks cut both ways. Step up transparency too much and the battle shifts to fees and market data. And if platform outages crop up again, regulators could swoop in when it hurts most.

Eyes are on LSEG’s FY 2025 preliminary numbers, set for release Feb. 26. Chief executive David Schwimmer and finance chief Michel‑Alain Proch plan to host a webcast then. Investors are watching for news on the buyback, any regulatory shifts, and appetite for LSEG’s market data and analytics.

Stock Market Today

  • Parabilis Plans IPO to Fund Phase 3 Trial for Tumor Drug Following Regeneron Deal
    May 20, 2026, 5:56 AM EDT. Parabilis Medicines, a Massachusetts biotech, is preparing for an initial public offering (IPO) to finance the phase 3 trial of its tumor drug zolucatetide, targeting rare desmoid tumors. The drug, which inhibits the Wnt/β-catenin pathway implicated in many cancers, recently received FDA fast-track status. Proceeds will also support phase 1 trials for additional cancers. Parabilis secured a $50 million upfront payment and a $75 million equity investment from Regeneron in a deal to explore Parabilis' helicon peptide platform. The firm boasts over $300 million in cash from prior funding rounds. CEO Mathai Mammen aims to grow Parabilis into a fully integrated research, development, manufacturing, and commercialization company, relying on partnerships to finance its ambitions.

Latest articles

San Antonio’s New Battery Bet Comes Just as CPS Outages Get Longer

San Antonio’s New Battery Bet Comes Just as CPS Outages Get Longer

20 May 2026
OCI Energy and CPS Energy have begun building a 120-megawatt battery storage facility in southeastern Bexar County, aiming for commercial operation in 2027. The project follows a rise in average outage duration for CPS Energy customers to 75.38 minutes in 2025. OCI will own the facility, with CPS holding operational control. ING is financing construction, and LG Energy Solution Vertech is supplying batteries.
Co-Diagnostics Jumps; $3 Million Deal Looms

Co-Diagnostics Jumps; $3 Million Deal Looms

20 May 2026
Co-Diagnostics announced a $3 million private placement after its stock surged 43.8% Tuesday, then fell 13.3% in after-hours trading. The company will sell 1.65 million shares or pre-funded warrants, plus warrants for up to 3.29 million more shares, nearly doubling its share count. The move follows its completion of a Bundibugyo virus assay as Ebola spreads in Congo and Uganda. Co-Diagnostics reported $8.2 million in cash at March 31.
Micron Stock Just Dodged the Nasdaq Selloff. A Samsung Strike Could Be Its Next Jolt

Micron Stock Just Dodged the Nasdaq Selloff. A Samsung Strike Could Be Its Next Jolt

20 May 2026
Micron Technology shares rose 2.5% Tuesday to $698.74, lifting its market value near $798 billion as the Nasdaq fell. Analysts cited tight memory supply and strong DRAM and NAND pricing. A planned strike by 48,000 Samsung workers Thursday could disrupt global memory supply, potentially raising prices. Micron recently sampled 256GB DDR5 server modules to partners.
AI stocks brace for a big week: Micron slips on Samsung HBM4 talk as Nvidia looms
Previous Story

AI stocks brace for a big week: Micron slips on Samsung HBM4 talk as Nvidia looms

India fintech MIDASX hits best quarter, turns cash-flow positive as it scales AI-led distribution
Next Story

India fintech MIDASX hits best quarter, turns cash-flow positive as it scales AI-led distribution

Go toTop